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ABSTRACT
Background and aims Teduglutide, a GLP-2 analogue,
mayrestoreintestinalstructuralandfunctionalintegrityby
promoting repair and growth of the mucosa and reducing
gastric emptying and secretion, thereby increasing ﬂuid
and nutrient absorption in patients with short bowel
syndrome (SBS). This 24-week placebo-controlled study
evaluated the ability of teduglutide to reduce parenteral
support in patients with SBS with intestinal failure.
Methods In 83 patients randomised to receive
subcutaneous teduglutide 0.10 mg/kg/day (n¼32),
0.05 mg/kg/day (n¼35) or placebo (n¼16) once daily,
parenteral ﬂuids were reduced at 4-week intervals if
intestinal ﬂuid absorption (48 h urine volumes) increased
$10%. Responders were subjects who demonstrated
reductions of $20% in parenteral volumes from baseline
at weeks 20 and 24. The primary efﬁcacy end point,
a graded response score (GRS), took into account higher
levels and earlier onset of response, leading to longer
duration of response. The intensity of the response was
deﬁned as a reduction from baseline in parenteral volume
(from 20% to 100%), and the duration of the response
was considered the response at weeks 16, 20 and 24.
The results were tested according to a step-down
procedure starting with the 0.10 mg/kg/day dose.
Results Using the GRS criteria, teduglutide in a dose of
0.10 mg/kg/day did not have a statistically signiﬁcant
effect compared with placebo (8/32 vs 1/16, p¼0.16),
while teduglutide in a dose of 0.05 mg/kg/day had
a signiﬁcant effect (16/35, p¼0.007). Since parenteral
volume reductions were equal (3536475 and
3546334 ml/day), the trend towards higher baseline
parenteral volume (181661008 vs 13746639 ml/day,
p¼0.11) in the 0.10 mg/kg/day group compared with the
0.05 mg/kg/day group may have accounted for this
discrepancy. Three teduglutide-treated patients were
completelyweanedoffparenteralsupport.Seriousadverse
eventsweredistributedsimilarlybetweenactivetreatment
groups and placebo. Villus height, plasma citrulline
concentration and lean body mass were signiﬁcantly
increased with teduglutide compared with placebo.
Conclusions Teduglutide was safe, well tolerated,
intestinotrophic and suggested pro-absorptive effects
facilitating reductions in parenteral support in patients
with SBS with intestinal failure.
ClinicalTrials.gov number NCT00172185.
INTRODUCTION
Short bowel syndrome (SBS) is characterised by
large heterogeneity where patients with intestinal
insufﬁciency are able to compensate for their
malabsorption of ﬂuids, electrolytes, trace
elements, vitamins or nutrients by increasing oral
intake and adapt metabolically,
1 2 whereas patients
with intestinal failure depend on parenteral support
(ﬂuids, electrolytes or nutrients).
3e5 A large part of
this heterogeneity is explained by differences in
the anatomy of the remnant bowel.
67Patients
with mild intestinal failure with a jejunostomy
or ileostomy need approximately 1000 ml of ﬂuid
and electrolytes taken over a few hours 3e7 times
per week. Patients with SBS with jejunostomies or
ileostomies frequently have complications such as
dehydration and electrolyte deﬁciencies due to
stomal losses. In severe cases, signiﬁcant protein
and energy malabsorption can occur and may
require supplementary hypertonic nutrients and
electrolyte infusions administered both daytime
and nocturnally. Patients with SBS and intestinal
failure who have a preserved colon in continuity
often suffer from large amounts of rectal ﬂuid loss,
fear of incontinence and the consequences of
colonic fermentation such as gaseous distension
and ﬂatulence, whereas ﬂuid and electrolyte
deﬁciencies are less prominent.
7 Since some of
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Signiﬁcance of this study
What is already known on this subject?
< In an open-label non-placebo controlled 21-day
phase 2 study, teduglutide has been shown to
increase intestinal wet weight absorption in
patients with short bowel syndrome using
metabolic balance studies.
What are the new ﬁndings?
< This is the ﬁrst long-term (24 weeks) rando-
mised placebo-controlled study of teduglutide in
patients with short bowel syndrome dependent
on parenteral support.
< Teduglutide was safe, well tolerated and led to
restoration of intestinal functional and structural
integrity through signiﬁcant intestinotrophic and
pro-absorptive effects.
How might it impact on clinical practice in the
foreseeable future?
< Teduglutide has the potential to reduce the
burden often seen with parenteral support in
patients with short bowel syndrome with
intestinal failure, and could add to the limited
clinical treatment armamentarium in treating
patients with short bowel syndrome.
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Small bowelthese patients do not imminently suffer from dehydration, days
off parenteral nutrients are possible. However, on those nights
when nutrient infusions are required, both the infusion and the
accompanying excessive urine production may disturb the sleep
pattern of the patients. In the most severe cases, nocturnal
nutrients as well as daytime ﬂuid and electrolytes are required.
Although frequently life-saving in patients with SBS with
intestinal failure, the parenteral administration of ﬂuids, elec-
trolytes, trace elements, vitamins and nutrients has been asso-
ciated with potentially life-threatening complications. Poor
catheter care technique, insertion site, tunnel and catheter-
related blood stream infections may lead to bacteraemia and
even septicaemia, and the presence of a central catheter may lead
to central venous thrombosis and even embolism.
5 In addition,
parenteral constituents and chronic dehydration may contribute
to progressive intestinal failure-associated liver and renal disease
and eventually failure.
89Mutually, the symptoms of SBS with
intestinal failure and the inconveniences and complications in
relation to parenteral support may cause potential restrictions in
the lifestyle of these patients and may lead to signiﬁcant
impairment of their quality of life.
10 11
In the past, the clinical care of patients with SBS has mainly
focused on ‘making the most of what the SBS patient still had’
by optimising remnant intestinal function through dietary
interventions, oral rehydration solutions, antidiarrhoeal and
antisecretory agents. Furthermore, anastomosis of excluded
bowel has been advocated, when it is possible, and experimental
surgical procedures have also been employed. Intestinal trans-
plantation is currently only recommended in patients failing
parenteral support due to recurrent life-threatening sepsis, loss
of venous access and end stage intestinal failure-associated liver
disease.
5 Treatments focused on improving the structural and
functional integrity of the remaining intestine by so-called
intestinal rehabilitation which minimise or eliminate the need
for parenteral support are therefore needed.
In recent years hormonal stimulation to augment remnant
bowel adaptation has been suggested, with glucagon-like peptide
2 (GLP-2)da peptide which is secreted from the intestinal L-cells
following ingestion of a mealdas a key factor. Repeated
administration of GLP-2 promotes the expansion of the intes-
tinal mucosa via the stimulation of crypt cell growth and the
reduction of enterocyte apoptosis.
12 Exogenous GLP-2 adminis-
tration inhibits gastric acid secretion and gastric emptying,
13 14
stimulates intestinal blood ﬂow,
15 increases intestinal barrier
function
16 and enhances nutrient and ﬂuid absorption in both
preclinical and clinical models.
17 In addition, GLP-2 may decrease
bone resorption and it has been suggested as a potential therapy
in osteoporosis.
18
Open uncontrolled clinical studies have suggested positive
effects of exogenously administered GLP-2 and the di-peptidyl
peptidase IV degradation resistant analogue, teduglutide, in
patients with SBS.
19e22 In an open-label 3-week study where the
oral intake and parenteral support were intentionally kept
constant during 72 h balances, teduglutide reduced faecal wet
weight excretions by 7116734 g/day (p¼0.001) and increased
wet weight absorption by 7436477 g/day causing increases in
urine volumes of 5556485 g/day (p<0.001). In addition, faecal
energy losses decreased by 80861453 kJ/day (p¼0.04) in relation
to teduglutide treatment, but all effects reverted 3 weeks after
treatment.
22
In the present study, the largest randomised placebo-controlled
trial ever performed in patients with SBS with intestinal failure,
the objective was to determine whether teduglutide could
reduce the burden of parenteral nutrition and intravenous ﬂuid
requirements. Secondary endpoints included theability to obtain
additional days off or eliminate the need for parenteral support
in this SBS population with demonstrated intestinal failure. In
detail, during 24 weeks of treatment with placebo or teduglutide,
adjustments in the parenteral support were performed when
the urine volume was increased to a certain threshold. This
algorithm-based approach considered the changes in urine
volumes to be based on changes in intestinal wet weight
absorption. In addition to safety evaluations, DEXA scanning,
histological evaluation of bowel morphology in biopsies, plasma
citrulline and quality of life questionnaires described changes in
body composition, structural intestinal adaptation and quality of
life,respectively,inrelationtoplaceboandteduglutidetreatment.
METHODS
Patients, study design, efﬁcacy and safety
After receiving approval from local IRBs and medical ethics
committees, centres screened patients of both sexes aged
$18 years with a history of SBS due to intestinal resection and
dependent on parenteral support (ﬂuids, electrolytes or nutri-
ents) at least three times per week for a period of at least
12 months prior to the start of the study. Exclusion criteria are
shown in box 1.
The basic study design is presented in ﬁgure 1.
Parenteral optimisation
To establish that the patients minimally tolerated baseline
parenteral support resulted in a urine output of 1.0e2.0 l/day,
a period of optimisation was used. The patients were instructed
how to perform home collections of their 48 h urine output and
Box 1 Exclusion criteria
< Pregnancy or lactation.
< Body mass index <18 or >27 kg/m
2.
< Active Crohn’s disease as evaluated by standard procedures
employed by the investigator.
< Radiation enteritis, scleroderma, coeliac disease, refractory or
tropical sprue, diabetes.
< Alcohol or drug abuse within the last year.
< Previous use of teduglutide or potential allergies to teduglutide
or its constituents.
< Inadequate hepatic function: ALT and AST both >2.03 upper
limit of normal (ULN), total bilirubin >1.253 ULN or alkaline
phosphatases >2.53 ULN.
< Inadequate renal function: serum creatinine or blood urea
nitrogen >1.53 ULN.
< Urine sodium <20 mmol/day.
< Any hospitalisation within 1 month before screening.
< Use of inﬂiximab, growth hormone or growth factors such as
native GLP-2 or other biological therapy within the last 12
weeks.
< Use of systemic corticosteroids, methotrexate, cyclosporine,
tacrolimus, sirolimus, octreotide, intravenous glutamine or any
investigational drug within last 30 days.
< The use of antimotility and antidiarrhoeal agents (loperamide,
difenoxylate, codeine and other opiates), H2-receptor antag-
onists, proton pump inhibitors, bile sequestering agents, oral
glutamine, diuretics and oral rehydration solutions were
required to be stable for $4 weeks prior to baseline
evaluations and remain stable during the study.
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Small bowelcompleted these 2 days before each visit. Although the osmo-
larity and oral intake were not kept strictly controlled, study
participants were asked to try to keep the timing, quantity and
quality of beverages as constant as possible during the 48 h
collection periods. The study subjects were seen in outpatient
clinics at 2-week intervals. Adjustment to the study subjects’
baseline parenteral volume was performed when urine volume
fell below 1.0 l/day or exceeded 2.0 l/day. At all times, interim
safety evaluations were performed within 1 week after adjusting
parenteral volumes by repeating 48 h urine collections, again
recording and keeping oral beverages the same as during previous
balances. Blood samples were taken (including haematocrit,
blood urea nitrogen and creatinine), urine sodium was measured
and a clinical evaluation was performed to check for clinical signs
of dehydration. If tolerated, the new parenteral volume was
maintained stable until the next visit and, if not, the original
parenteral volume was resumed. The patient was excluded from
the study if parenteral optimisation was not achieved, deﬁned as
stable urine output volume of 1.0e2.0 l/day after 8 weeks.
Parenteral stabilisation
After optimisation, the patients were maintained for 4e8 weeks
on the stabilised tolerated parenteral volume. If the patients still
had a urine volume of 1.0e2.0 l/day while keeping oral beverages
constant, the patients were eligible for randomisation.
Randomisation
Eligible patients were randomly assigned to one of three groups
according to a computer-generated interactive response system
(Fisher Automated Clinical Trial Services). Randomisation was
stratiﬁed for the three groups and the parenteral volume at three
levels of consumption: (1) parenteral volume consisting of
intravenous ﬂuids and electrolytes only (3e7 times weekly); (2)
parenteral volume consisting of ﬂuids and nutrients 3e5 times
weekly; and (3) parenteral volume consisting of ﬂuids and
nutrients (6e7 times weekly). These patients with SBS,
depending on their parenteral support (nutrients and/or ﬂuids),
were randomised to receive teduglutide (Cangene, Winnipeg,
Manitoba, Canada) at doses of 0.05 or 0.10 mg/kg/day or
placebo (2:2:1) given subcutaneously into one of the four
quadrants of the abdomen or either thigh once daily in the
morning for 24 weeks. The placebo consisted of a lyophilised
powder containing L-histidine, mannitol, monobasic and dibasic
sodium phosphate, which were also contained in the active
treatment.
Parenteral adjustments after randomisation
A strict parenteral weaning algorithm was used in the protocol
that allowed for no more than 10% reductions in parenteral
volumes at 4-week intervals (ﬁgure 2). Weaning was performed
if the 48 h urinary volumes exceeded the baseline values by more
than 10%, regardless of the absolute amount. Comparisons for
subsequent reductions were always made to baseline urinary
volumes. Greater reductions were allowed if urinary volumes
exceeded 2.0 l/day. A maximum of ﬁve reductions in parenteral
support were allowed from baseline to week 24. The physician
responsible for adjusting the parenteral support was expert in
the management of intestinal failure and parenteral infusion
weaning. The physicians were educated in the algorithm and
instructed to follow it. This physician was required to be
Figure 1 Basic study design. AE, adverse event.
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Small boweldifferent from the person conducting the physical examinations
and assessing safety because the observation of stomal swelling,
known to occur in relation to GLP-2 and teduglutide treatment,
may have unblinded the observer.
22 The mode of parenteral
adjustments, either by adjusting daily parenteral provisions or
providing days off parenteral support, was entrusted to this
person and was not speciﬁed in the protocol. As previously
described, interim safety evaluations were performed within the
week following adjustment to parenteral volumes. This was
done by repeating 48 h urine collections, attaining weights and
by reviewing the recorded oral ﬂuid intakes as per the previous
balance studies leading to a change in parenteral support in the
algorithm. Blood samples were taken (including haematocrit,
creatinine, blood urea nitrogen), urine sodium was measured and
a clinical evaluation was performed checking for clinical signs of
dehydration. Only if this assessment led to a conclusion that the
new parenteral volume was tolerated would the weekly paren-
teral support volume be maintained until the next visit.
Otherwise, the original parenteral volume was resumed.
The primary efﬁcacy variable in the study was initially the
responder ratedthat is, the percentage of patients who had
a reduction from baseline in parenteral volume of $20% at week
20 of treatment and again at week 24. A decrease of at least 20%
in parenteral ﬂuid was considered to result in a clinical beneﬁtt o
the patients. After an independent review of the protocol by
a statistical and regulatory panel prior to database lock, an
expanded graded primary end point was introduced to compare
the patients treated with teduglutide versus placebo with
respect to a graded response score (GRS) criterion that accounted
for both intensity and duration of a response at the end of the
24-week period. The intensity of the response relied on a reduc-
tion from baseline in weekly parenteral volume (from 20% to
100%). The duration of the response considered the responses at
weeks 16 and 20, as well as weeks 20 and 24. The analysis of this
expanded end point took into account higher levels of response
and earlier onset of response coupled with a longer duration of
response as shown in table 1. Thus, the score arose from the
concept that, optimally, a graded change could be seen at the
earlier time point and still observed at the later time point.
The statistical analysis of the GRS score compared the effects
of placebo and teduglutide, starting with the 0.10 mg/kg/day
dose according to a pre-speciﬁed step-down procedure.
Secondary efﬁcacy end points included the number and
percentage of subjects who responded (deﬁned as a parenteral
volume reduction of $20% from baseline at week 20 and
maintained at week 24); the absolute reduction from baseline in
parenteral volume and parenteral kilojoules; achievement of at
least one day reduction in weekly parenteral administration or
Figure 2 Algorithm for parenteral volume adjustment during dosing.
Table 1 Criterion values for the graded response score
Week 20 maintained at week 24
<20% reduction
in PV
20e39%
reduction in PV
40e99%
reduction in PV
100% reduction
in PV
Week 16 maintained to week 20 <20% reduction in PV 0 1 2 3
20e39% reduction in PV 0 2 3 4
>40% reduction in PV 0 3 4 5
The criterion values relied on the timing and reduction from baseline in weekly parenteral volumes (PV). The protocol-deﬁned reduction was set at a minimum of 20% and a maximum of 100%.
The timing of onset and the duration of response incorporated the responses at week 16 maintained to week 20 and week 20 maintained at week 24.
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points included the change from baseline in oral ﬂuid intake and
urine production, body composition (evaluated by DEXA),
22
plasma citrulline (an amino acid produced by enterocytes as
a biomarker of a reduced enterocyte mass),
23 bowel morphology
(histopathological evaluation and villus height and crypt
depth morphometrics, optionally taken via stomas or by
colonoscopy)
22 and health-related quality of life questionnaires
(SF-36,
24 the EuroQol EQ-5D
25 and the IBDQ
26).
Safety evaluations were conducted throughout the study,
which included all reports of adverse events (AEs) and clinical
laboratory tests. An independent data and safety monitoring
committee oversaw the study.
All patients completing the randomised 24-week placebo-
controlled trial were offered active treatment in a 28-week
extension trial. The results from this study will be presented in
a separate publication.
Statistical analysis
Based on the previous ﬁndings in a phase 2 study,
22 the
prospective primary hypothesis was that subcutaneous injec-
tions of teduglutide would result in a higher GRS than placebo
in patients with SBS dependent on parenteral support. The
statistical analysis plan speciﬁed a step-down procedure which
required teduglutide at a dose of 0.10 mg/kg/day to be statisti-
cally signiﬁcantly greater than placebo before evaluation of
the 0.05 mg/kg/day dose. Statistical analyses were performed on
the intent-to-treat population. The analysis of AEs included all
83 patients who received at least one dose of the assigned
treatment. Results are expressed as mean6SD.
All statistical tests were two-sided with an a level of 0.05. A
sample size of 80 randomised subjects (32 subjects in each of the
two teduglutide treatment groups and 16 subjects in the placebo
group) was required to provide at least 90% power to detect an
increase in the percentage of subjects who had the protocol-
deﬁned minimum response deﬁned as a parenteral volume
decrease of $20% for week 20 and maintained at week 24
which, on average, was estimated to correspond to one day off
parenteral support (from 5% in the placebo treatment group to
50% in the teduglutide treatment groups in the study). The
power calculations were based on two-sided tests of signiﬁcance
using the Fisher exact test.
For the analysis of the primary efﬁcacy end point (the GRS),
pairwise treatment comparisons were made using a rank anal-
ysis of covariance (an extension of the Wilcoxon rank sum test)
with strata for the baseline parenteral consumption level used
for the stratiﬁcation of the randomisation and treatment groups,
with the baseline weekly parenteral volume as a covariate and
a step-down procedure for multiple comparisons. For the main
secondary end point (responses maintained from week 20 and
week 24 and deﬁned as a $20% reduction from baseline in
weekly parenteral volume), pairwise comparisons between
treatment groups were made using the Fisher exact test.
RESULTS
Patients
In the period from May 2004 to November 2007, 139 patients
signed informed consent forms and were screened at 32 centres
in the USA, Canada, Denmark, France, Poland, Germany, the
Netherlands, the UK and Belgium. Eighty-four patients with
SBS were randomised and 83 were dosed (ﬁgure 1). The study
data were gathered by the investigators and by a contract
research organisation, and the data were held and analysed by
NPS Pharmaceuticals in collaboration with the principal inves-
tigators on the writing team who had access to all data.
There were no signiﬁcant differences in the demographic
characteristics and medications among the groups at baseline
compared with the placebo group, although parenteral volume
and energy infusions tended to be higher in the 0.10 mg/kg/day
teduglutide group (table 2). The numbers of patients completing
the 24-week study were 15 (94%), 29 (88%) and 27 (77%) in the
placebo, 0.10 mg/kg/day teduglutide and 0.05 mg/kg/day tedu-
glutide groups, respectively.
Efﬁcacy
Primary efﬁcacy end point: GRS
The primary efﬁcacy end point of the study, the GRS, was not
signiﬁcantly different from placebo in the teduglutide 0.10 mg/
kg/day group (p¼0.16), although a greater frequency of higher
category responses was seen (table 3).
Ad hoc analysis of the primary efﬁcacy end point
The prespeciﬁed statistical analysis plan required the 0.10 mg/
kg/day dose to be signiﬁcantly greater than placebo before
further analyses. To gain further understanding about the effect
of teduglutide, it was decided to explore the effect of the
0.05 mg/kg/day dose on the primary end point. These results
showed a statistically signiﬁcant improvement compared with
placebo in the GRS for the 0.05 mg/kg/day teduglutide dose
group (p¼0.007).
Secondary and exploratory efﬁcacy end points
The binary response end point represented the proportion of
patients that responded to treatment which was deﬁned as the
achievement of a $20% reduction from baseline in weekly
parenteral volume at week 20 and maintained at week 24. The
responder rate was not signiﬁcantly different between the
teduglutide 0.10 mg/kg/day dose group and the placebo group
(25% (8/32) vs 6% (1/16), p¼0.17), but the responder rate was
signiﬁcantly higher in the teduglutide 0.05 mg/kg/day dose group
compared with placebo (46% (16/35) vs 6% (1/16), p¼0.005).
Three subjects were completely weaned from parenteral
support; two patients in the 0.05 mg/kg/day teduglutide treat-
ment group became completely independent of parenteral
support after 25 and 6.5 years on this treatment, receiving 5.4 l
and 3.5 l parenteral support per week at baseline, respectively.
Another patient receiving the 0.10 mg/kg/day teduglutide dose,
who had been receiving parenteral support for 3.7 years and
received 4.5 l parenteral support at baseline, was also completely
weaned from parenteral support at the end of treatment at week
24. Neither active treatment arm resulted in a signiﬁcant
reduction in the number of days on parenteral support.
As shown in ﬁgure 3, a minor but statistically signiﬁcant
reduction in parenteral volume was observed in patients in the
placebo group at weeks 12 and 24 compared with baseline
(1066167 ml/day, p¼0.02 and 1286202 ml/day, p¼0.03,
respectively). No signiﬁcant changes were seen in the oral ﬂuid
intake or urine volume in the placebo group.
Despite not meeting the a priori end point of a minimum
reduction of 20% in parenteral ﬂuid volume at weeks 20 and 24,
patients receiving the teduglutide 0.10 mg/kg/day dose reduced
their oral ﬂuid intake by 3426599, 2506624, 3656575,
3076525, 3596638 and 3926647 ml/day at weeks 4, 8, 12, 16,
20 and 24, respectively, compared with baseline (all p<0.05).
Oral ﬂuid intake was signiﬁcantly lower than placebo at weeks
12 and 20 (4476526 ml/day and 6676738 ml/day, p<0.05). Oral
ﬂuid intake in this group (teduglutide 0.10 mg/kg/day) initially
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Small bowelTable 2 Demographic characteristics and medication at baseline
Placebo (n[16)
Teduglutide
0.10 mg/kg/day
(n[32)
Teduglutide
0.05 mg/kg/day
(n[35) Overall (n[83) p Value
Age (years), mean (SD) 49.4 (15.1) 50.3 (14.0) 47.1 (14.2) 48.8 (14.2)
N 16 32 35 83 0.64y
Range (20e72) (19e79) (20e68) (19e79)
BMI (kg/m
2), mean (SD) 22.0 (2.9) 21.7 (2.6) 21.2 (3.0) 21.5 (2.8)
N 16 32 35 83 0.60y
Range (17.4e28.4) (17.0e26.4) (15.6e26.7) (15.6e28.4)
Female sex, n (%) 9 (56.3%) 19 (59.4%) 18 (51.4%) 46 (55.4%) 0.81*
Cause of major intestinal resection, n (%) 0.81*
Crohn’s disease 7 (44%) 13 (41%) 10 (29%) 30 (36%)
Vascular disease 3 (19%) 8 (25%) 14 (40%) 25 (30%)
Injury 1 (6%) 2 (6%) 3 (9%) 6 (7%)
Volvulus 2 (13%) 4 (13%) 5 (14%) 11 (13%)
Other 3 (19%) 5 (16%) 3 (9%) 11 (13%)
Patients in whom the intestinal anatomy
or remnant small bowel length was
unknown
0 213
Jejunostomy/ileostomy, n 0.22*
Ileostomy 1 7 2 10
Jejunostomy 4 4 6 14
Colon in continuity, n (%) 11 (69%) 19 (59%) 26 (74%) 56 (68%)
Overall remnant small bowel length, cm 0.40y
N 1 5 2 73 17 3
Mean (SD) 77 (53) 68 (43) 58 (44) 66 (45)
Median 60 60 50 60
Range (15e200) (10e200) (6e200) (6e200)
Remnant small bowel length in patients
with jejunostomy/ileostomy, cm
0.19y
N 4 871 9
Mean (SD) 144 (52) 77 (60) 105 (54) 101 (59)
Median 150 52 80 75
Range (75e200) (30e200) (60e200) (30e200)
Remnant small bowel length in patients
with colon in continuity, cm
0.15y
N 1 1 1 72 45 2
Mean (SD) 53 (26) 62 (27) 45 (29) 52 (28)
Median 50 60 40 50
Range (15e110) (10e120) (6e125) (6e125)
Remnant colon, n (%) 0.76*
>25e50% colon remnant 4 (36%) 8 (42%) 7 (27%) 19 (34%)
>50e75% colon remnant 4 (36%) 4 (21%) 9 (35%) 17 (30%)
>75e100% colon remnant 3 (27%) 7 (37%) 10 (39%) 20 (36%)
Time on parenteral support, years 0.79y
N 1 6 3 23 58 3
Mean (SD) 7.9 (7.5) 7.3 (5.9) 6.6 (6.5) 7.1 (6.4)
Range (1e23) (1e24) (1e24) (1e24)
Parenteral volume, ml/day 0.11y
N 1 6 3 23 48 2
Mean (SD) 1531 (874) 1816 (1008) 1374 (639) 1577 (859)
Range (742e3850) (470e4643) (333e2500) (333e4643)
Parenteral energy, kJ/day
N 16 32 35 83 0.046y
Mean (SD) 3385 (2591) 5296 (2845) 3992 (2689) 4378 (2805)
Range (0e9984) (0e13749) (0e11514) (0e13749)
Number of patients in parenteral type
stratiﬁcation
0.52z
Type group 1, n (%) 4 (25%) 3 (9%) 8 (23%) 15 (18%)
(No with 3/4/5/6/7 days PS/week) (1/0/0/2/1) (0/0/1/0/2) (1/2/0/1/4) (2/2/1/3/7)
Type group 2, n (%) 8 (50%) 18 (56%) 19 (54%) 45 (54%)
(No with 3/4/5/6/7 days PS/week) (2/4/1/0/1) (3/5/6/4/0) (5/7/6/0/0) (10/16/13/4/1)
Type group 3, n (%) 4 (25%) 11 (34%) 8 (23%) 23 (28%)
(No with 3/4/5/6/7 days PS/week) (0/0/0/0/4) (0/0/0/2/9) (0/0/0/0/8) (0/0/0/2/21)
Continued
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Small bowelincreased urine production by 2106537 ml/day at week 4
compared with baseline (p¼0.04), but urine production subse-
quently decreased to baseline levels. In addition, parenteral
volume was gradually decreased by 1596342, 2426361,
2756367, 3096431 and 3536475 ml/day at weeks 8, 12, 16, 20
and 24, respectively (all p<0.05) compared with baseline. These
parenteral volume reductions were not signiﬁcant when
compared with placebo (p¼0.08 at week 24).
Demonstrating a consistent effect, patients receiving the
teduglutide 0.05 mg/kg/day dose produced signiﬁcantly more
urine at all time points (2606521, 2076485, 2886477,
2136261, 3066567 and 3676485 ml/day at weeks 4, 8, 12, 16,
20 and 24, all p<0.05 vs baseline), in spite of maintaining
a constant oral ﬂuid intake and having parenteral volume
signiﬁcantly decreased by 1096230, 1936223, 2466277,
3196295 and 3546334 ml/day at weeks 8, 12, 16, 20 and 24 (all
p<0.05), respectively, compared with baseline (ﬁgure 3). At week
24 both active treatment arms exhibited a mean weekly reduc-
tion in parenteral volume of  2.5 l compared with  0.9 l for
placebo (p¼0.08 for each comparison of active versus placebo).
Reductions in parenteral energy at week 24 of 2436450 kJ/
day (p¼0.056), 44761051 kJ/day (p¼0.030) and 91261333 kJ/
day (p¼0.001) were seen in the placebo group, teduglutide
0.10 mg/kg/day group and the teduglutide 0.05 mg/kg/day
group, respectively, compared with baseline. However, the
reductions in parenteral energy were not signiﬁcant between
active teduglutide (0.10 mg/kg/day and 0.05 mg/kg/day) and
placebo (p¼0.11). Oral energy intake and faecal excretion were
not measured.
Body weight was measured at all time points, while DEXA
scans were only performed at baseline and at week 24. As shown
in table 4, statistically signiﬁcant increases in body weight were
seen in the two teduglutide dose groups at various time points
compared with placebo. These changes were mainly conﬁned to
the lean body mass, as illustrated in table 5.
A statistically signiﬁcant increase in the total body bone
mineral content was observed after 24 weeks of treatment with
teduglutide 0.10 mg/kg/day (p¼0.046), and a numerical increase
was also seen in the teduglutide 0.05 mg/kg/day dose group
(p¼0.06, table 5) versus placebo. However, no signiﬁcant
changes in regional Z- or T-scores, reﬂecting bone mineral
density, were demonstrated in this study (data not shown).
To demonstrate direct restoration of structural integrity of the
intestine, changes in bowel morphology were evaluated in
a subset of patients who were willing to have a biopsy taken
(table 6). Signiﬁcant increases in small bowel villus height were
seen in both teduglutide dose groups compared with baseline
and placebo. Signiﬁcantly increased colonic crypt depths
compared with placebo (p¼0.016) were seen at the 0.10 mg/kg/
day dose. At baseline, plasma citrulline, a biomarker of reduced
enterocyte mass in patients with SBS, was lower in the
0.10 mg/kg/day teduglutide group than in the placebo group
(p¼0.051). Plasma citrulline increased signiﬁcantly in both
teduglutide groups compared with baseline and placebo.
Table 2 Continued
Placebo (n[16)
Teduglutide
0.10 mg/kg/day
(n[32)
Teduglutide
0.05 mg/kg/day
(n[35) Overall (n[83) p Value
Number of patients in parenteral volume
stratiﬁcation
0.43z
Parenteral volume 0e7 l/week, n (%) 6 (38%) 9 (28%) 14 (40%) 29 (35%)
(No with 3/4/5/6/7 days PS/week) (2/3/0/1/0) (3/5/0/1/0) (5/6/0/0/2) (10/14/0/2/3)
Parenteral volume 7e14 l/week, n (%) 6 (38%) 13 (41%) 11 (31%) 30 (36%)
(No with 3/4/5/6/7 days PS/week) (1/1/1/0/3) (0/0/6/5/2) (1/2/5/1/2) (2/3/12/6/7)
Parenteral volume 14e21 l/week, n (%) 3 (19%) 6 (19%) 9 (26%) 18 (22%)
(No with 3/4/5/6/7 days PS/week) (0/0/0/1/2) (0/0/1/0/5) (0/1/1/0/7) (0/1/2/1/14)
Parenteral volume >21 l/week, n (%) 1 (6%) 4 (13%) 0 (0%) 5 (6%)
(No with 3/4/5/6/7 days PS/week) (0/0/0/0/1) (0/0/0/0/4) (0/0/0/0/0) (0/0/0/0/5)
Concomitant medication
Antidiarrhoeal agents, n (%) 8 (50%) 19 (59%) 22 (63%) 49 (59%)
Antisecretory agents, n (%) 7 (44%) 17 (53%) 19 (54%) 43 (52%)
*p Value based on the c
2contingency table using the exact method.
yp Value calculated using the general linear model (GLM) method with corresponding variables as dependent variables and treatment group as the independent variable.
zp Values for overall treatment comparisons based on the Fisher exact test for categorical variables and on a one-way ANOVA with effect for treatment for continuous variables.
Parenteral type group 1: parenteral support consisting of intravenous ﬂuids and electrolytes only (3e7 times weekly); parenteral type group 2: parenteral nutrition 3e5 times weekly; parenteral
type group 3: parenteral nutrition 6e7 times weekly.
PS, parenteral support.
Table 3 Summary of results for the graded response score (GRS)
Criterion value
01 2 3 4 5
<20% reduction in
parenteral support
Off parenteral
support
Placebo 15 (94%) 0 (0%) 1 (6%) 0 (0%) 0 (0%) 0 (0%)
Teduglutide 0.10 mg/kg/day 24 (75%) 2 (6%) 4 (13%) 0 (0%) 2 (6%) 0 (0%)*
Teduglutide 0.05 mg/kg/day 19 (54%) 6 (17%) 6 (17%) 0 (0%) 2 (6%) 2 (6%)
Number (%) of patients within the criterion value groups.
Comparison of 0.10 mg/kg/day of teduglutide vs placebo, p¼0.16. Comparison of 0.05 mg/kg/day teduglutide vs placebo, p¼0.007. p Value based on a rank ANCOVA adjusting for multiple
comparisons in the primary efﬁcacy analysis.
*One patient was weaned off parenteral support at week 24 with a score of 4.
For GRS score, refer to table 1.
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Small bowelThese increments were higher in the 0.10 mg/kg/day teduglutide
group.
The overall results from three quality of life assessments
(SF-36, EuroQol EQ-5D and IBDQ) indicated no major effect on
quality of life parameters (data not shown).
Safety and tolerability
Both doses of teduglutide were well tolerated throughout the
24 weeks of observation. The overall compliance was >85% in
all treatment groups. Of the 83 patients included in the study, 79
(95%) experienced at least one AE. The number of patients with
AEs and serious adverse events (SAEs) and treatment-emergent
AEs and SAEs leading to discontinuation of treatment is given in
table 7.
The most common AEs in the teduglutide treatment groups
were abdominal pain (24%), headache (24%), nausea (22%),
nasopharyngitis (16%) and vomiting (15%). The most
frequently reported SAEs were catheter-related complications,
catheter sepsis, catheter site infection, small intestinal
obstruction and fever. No deaths were reported during the
active treatment phase of the study. One patient died from
a bleeding ulcer during the screening phase of the study.
Figure 3 Overall effects of placebo, teduglutide 0.10 mg/kg/day and teduglutide 0.05 mg/kg/day at baseline and weeks 4, 8, 12, 16, 20 and 24 on the
reduction in oral ﬂuid intake, increase in urine volume and reductions in daily parenteral volume based on the 48 h measurements at home. The ﬁgure
also shows the composite effect, which is the sum of these beneﬁcial combined effects.
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Small bowelNo major ﬁndings were reported in the laboratory/chemistry or
haematology tests of the teduglutide-treated patients compared
with placebo.
Histopathological evaluation of the intestinal tissue samples
conﬁrmed no dysplastic transformation in any of the biopsies.
DISCUSSION
This study is the largest randomised placebo-controlled clinical
trial ever performed on treatment in patients with SBS. The
results of this study show that further exploration of teduglu-
tide as a therapeutic option in restoring structural and func-
tional intestinal integrity in patients with SBS with
demonstrated intestinal failure is warranted. Teduglutide at
0.05 mg/kg/day signiﬁcantly increased both the GRS (p¼0.007)
and the responder rate (p¼0.005) compared with placebo. Many
of the secondary end points were positive using either of the
teduglutide doses. Contrary to expectation of a dose response,
teduglutide at 0.10 mg/kg/day did not meet statistical signiﬁ-
cance in increasing the GRS or responder rate compared with
placebo. Although the primary hypothesis was therefore not
supported, the ﬁndings from the ad hoc analysis with the
0.05 mg/kg/day group suggest that the non-signiﬁcance of the
0.10 mg/kg/day dose versus placebo could be explained by
limitations imposed by the protocol and a trend towards larger
baseline parenteral volume requirements in the 0.10 mg/kg/day
group.
When considering the trial design and end points for this
study, it is paramount to address both the numerator and the
Table 4 Changes in mean6SD body weight (kg)
Baseline Week 4 Week 8 Week 12 Week 16 Week 20 Week 24
Placebo n¼16 n¼16 n¼16 n¼16 n¼15 n¼16 n¼16
61.369.7  0.161.3 0.061.5 0.361.6  0.461.8  0.362.7 0.263.1
Teduglutide 0.10 mg/kg/day n¼32 n¼32 n¼31 n¼30 n¼30 n¼29 n¼29
60.1610.1 0.961.5** 1.161.5*** 1.261.8*** 1.662.2*** 1.662.1*** 1.462.5**
p Value vs placeboy 0.69 0.06 0.03 0.38 0.009 0.01 0.18
Teduglutide 0.05 mg/kg/day n¼35 n¼35 n¼30 n¼28 n¼30 n¼28 n¼27
59.068.4 1.061.5*** 1.161.7*** 0.864.6 1.262.4* 1.162.7* 1.262.8*
p Value vs placeboy 0.38 0.02 0.03 0.60 0.03 0.06 0.31
Values shown are mean6SD.
*p<0.05, **p<0.01, ***p<0.001 vs baseline within the same treatment group (t test).
yp Value vs placebo for pairwise treatment differences from a general linear model (GLM) method with changes from baseline in corresponding variables as dependent variables and treatment
as the main effect, and baseline values of corresponding variables and baseline parenteral consumption levels (indicator variable) as covariates.
Table 5 Changes in body composition by DEXA
Placebo
(n[16)
Teduglutide
0.10 mg/kg/day
(n[32) p1 Value
Teduglutide
0.05 mg/kg/day
(n[35) p2 Value
FM, kg
Baseline n¼16 n¼31 0.80 n¼34 0.12
15.9565.50 15.4666.55 13.2265.78
Week 24 n¼14 n¼29 0.66 n¼28 0.07
16.5064.94 15.6466.70 13.1065.93
Absolute change n¼14 n¼29 0.19 n¼27 0.86
 0.6361.88 0.3861.98  0.3462.38
Relative change (%) n¼14 n¼29 0.21 n¼27 1.00
 3.8611.0 4.6616.5  1.6622.2
LBM, kg
Baseline n¼16 n¼31 0.60 n¼34 0.89
42.4267.82 41.1967.50 42.7768.28
Week 24 n¼14 n¼29 0.55 n¼28 0.37
41.5268.64 43.1267.87 43.9768.19
Absolute change n¼14 n¼29 0.004 n¼27 0.06
 0.5261.18 1.5362.37 0.8262.17
Relative change (%) n¼14 n¼29 0.0033 n¼27 0.051
 1.463.0 3.865.9 2.065.2
TBBMC, kg
Baseline n¼16 n¼31 0.003 n¼34 0.03
2.4260.47 2.0060.41 2.1060.47
Week 24 n¼15 n¼29 0.017 n¼28 0.079
2.3960.50 2.0460.42 2.1460.40
Absolute change n¼15 n¼29 0.046 n¼27 0.06
 0.01660.05 0.01060.045 0.00960.048
Relative change (%) n¼15 n¼29 0.045 n¼27 0.09
 0.862.1 0.662.4 0.462.4
Values shown are mean6SD.
p1 and p2 values for treatment differences from a general linear model (GLM) method with dependent variable changes from baseline
in the corresponding variables, independent variable treatment and corresponding variables at baseline as covariates.
FM, fat mass; LBM, lean body mass; TBBMC, total body bone mineral content.
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Small boweldenominator in the equation used to determine parenteral
volume and support while searching for a logical explanation for
the discrepancy in effect between the two teduglutide doses.
The numerator is best illustrated in ﬁgure 3 which shows in
detail the overall effects of placebo, teduglutide 0.10 mg/kg/day
and teduglutide 0.05 mg/kg/d dose at baseline and weeks 4, 8,
12, 16, 20 and 24 on the reduction in oral ﬂuid intake, the
increase in urine volume and reductions in daily parenteral
volume based on 48 h measurements at home. The ﬁgure also
illustrates the composite effect, which is the sum of these
positive combined effects.
This ﬁgure conﬁrms that patients receiving the 0.05 mg/kg/
day dose had a constant oral ﬂuid intake throughout the study.
However, since urine output increased steadily during the study,
this is in contravention to the objective of the study protocol
which was to maintain a constant urine output by progressively
reducing the parenteral volumes. Thus, the absolute effect of
teduglutide 0.05 mg/kg/day on the reduction in parenteral
volume (the numerator) appears to be underestimated. This may
be explained by the restrictions in the weaning algorithm (ie, the
maximally allowed reductions in parenteral support of 10% per
month) or varying degrees of protocol adherence of personnel
responsible for adjustments in parenteral support used in 32
centres around the globe. It can be hypothesised that a more
liberal protocol allowing for more aggressive adjustments in the
parenteral regimen or a better adherence to the parenteral
weaning algorithm may have yielded a similar result for the two
active treatment groups. Highlighting the total effect of the
0.05 mg/kg/day teduglutide dose, the composite end point
increased signiﬁcantly by 8166982 ml/day compared with
placebo (p¼0.03) at week 20.
When addressing the absolute effects of the 0.10 mg/kg/day
teduglutide dose, it is obvious that this dose led to a reduction in
oral ﬂuid intake which was evident throughout the study
(ﬁgure 3). According to the protocol, the parenteral volume could
not be reduced until after 4 weeks of teduglutide treatment and,
unless urine output exceeded 2 l/day, only monthly decrements
of 10% of baseline parenteral volumes were allowed. It is likely
that the patients with SBS receiving the high dose of teduglutide
adjusted their oral ﬂuid intake in order to reduce excessive
urine production (ﬁgure 3) and prevent ﬂuid retention, as also
demonstrated by increases in body weight and lean body mass
Table 6 Short bowel (SB) villus height and crypt depth, colonic crypt depth and plasma citrulline levels
Placebo
(n[16)
Teduglutide
0.10 mg/kg/day
(n[32) p1 Value
Teduglutide
0.05 mg/kg/day
(n[35) p2 Value
SB villus height, mm
Baseline n¼9n ¼20 0.97 n¼17 0.65
4286119 4276102 410683
Week 24 n¼7n ¼16 0.0004 n¼18 0.0008
347674 5936145 6006166
Absolute change n¼4n ¼14 0.0024 n¼11 0.0065
 1396169 1816156 1576132
Relative change (%) n¼4n ¼14 0.0086 n¼11 0.024
 24.4628.3 47.4642.3 40.4636.6
SB crypt depth, mm
Baseline n¼9n ¼20 0.03 n¼18 0.40
194664 151638 172663
Week 24 n¼7n ¼17 0.017 n¼18 0.006
135640 222685 198650
Absolute change n¼4n ¼15 0.008 n¼12 0.20
 27612 87680 16666
Relative change (%) n¼4n ¼15 0.0026 n¼12 0.11
 17.567.7 64.4652.1 17.8635
Colon crypt depth, mm
Baseline n¼9n ¼22 0.89 n¼20 0.27
395644 392667 4386109
Week 24 n¼10 n¼17 0.008 n¼17 0.015
375659 453672 441665
Absolute change n¼7n ¼17 0.022 n¼14 0.13
 3664 66685 96106
Relative change (%) n¼7n ¼17 0.016 n¼14 0.14
 0.5617.0 20.0627.1 5.1618.6
Plasma citrulline, mmol/l
Baseline n¼16 n¼32 0.051 n¼34 0.19
22.2610.6 16.668.3 18.0610.3
Week 24 n¼16 n¼29 0.09 n¼27 0.27
24.2613.6 32.1615.4 29.5616.2
Absolute change n¼16 n¼29 <0.0001 n¼26 <0.0001
1.965.0 15.7612.7 10.9611.3
Relative change (%) n¼16 n¼29 <0.0001 n¼26 <0.0001
7.9620.5 113.1684.0 66.7666.9
Values shown are mean6SD.
p1 and p2 values for treatment differences from a general linear model (GLM) method with dependent variable changes from baseline
in corresponding variables, independent variable treatment and corresponding variables at baseline as covariates.
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Small bowel(tables 4 and 5). These ﬁndings are encouraging in that they
demonstrate consistency with previous investigations showing
that increases in intestinal wet weight absorption led to
a reduction in oral ﬂuid intake in patients with SBS if the par-
enteral volume was kept constant.
20 It is possible that an earlier
and more aggressive intervention would have enabled
more substantial parenteral weaning, precluding the reduction in
oral ﬂuid intake. However, it is also possible that the high dose of
teduglutide may have inﬂuenced gastric motility which
may have led to decreased oral ﬂuid intake, but this would not
lead to increases in urine production at the same time (week 4,
ﬁgure 3). Highlighting the total absolute effect of the 0.10 mg/
kg/d teduglutide dose, the composite effect increased signiﬁ-
cantly by 4896619, 7006723 and 9536830 ml/day at weeks 12,
16 and 20, respectively (all p values <0.05) compared with
placebo.
Summarising the effects on the composite effect of the two
teduglutide doses, the urine volume increased by w350 ml/day
and the parenteral volume was decreased by w350 ml/day in the
0.05 mg/kg/day teduglutide dose group, whereas the oral ﬂuid
intake decreased by w350 ml/day and the parenteral volume
decreased by w350 ml/day in the 0.10 mg/kg/day teduglutide
dose group. Thus, the effects on the reduction on the parenteral
volume, the numerator, is equivalent with the two teduglutide
doses and the true effect of either teduglutide dose on intestinal
wet weight absorption is probably around 700 ml/day (ie, 4.9 l/
week), without taking into account the positive effects on the
ﬂuid balance evaluated by the lean body mass in DEXA scans
and body weight. This is highly consistent with ﬁndings in the
phase 2 study where true metabolic and ﬂuid balance studies
suggested an effect of teduglutide in doses ranging from 0.03 to
0.15 mg/kg/day on wet weight absorption equivalent to
7436477 g/day.
22
Turning to the denominator of the equation, it is noteworthy
that, although not consistently statistically signiﬁcant, imbal-
ances between patients with SBS receiving 0.10 mg/kg/day and
0.05 mg/kg/day teduglutide were evident. Remnant small bowel
length and plasma citrulline tended to be lower in the patients
with SBS receiving the 0.10 mg/kg/day dose than in those
receiving the 0.05 mg/kg/day dose at baseline and, more impor-
tantly, the parenteral energy and speciﬁcally baseline parenteral
volume tended to be higher in the 0.10 mg/kg/day teduglutide
group than in the 0.05 mg/kg/day teduglutide group (1.82 l/day
vs 1.37 l/day, table 1). In addition, the number of patients who
received >21 l parenteral ﬂuid per week was higher in the
0.10 mg/kg/day teduglutide group than in the 0.05 mg/kg/day
teduglutide dose group (13% vs 0%). The relative parenteral
volume reductions (18626%) in the 0.10 mg/kg/day teduglutide
group were therefore numerically lower than in the 0.05 mg/kg/
day teduglutide group (28628%), while the absolute parenteral
volume reductions at week 24 were comparable in the two
groups (3536475 ml/day and 3546334 ml/day, respectively,
ﬁgure 3). This may have contributed to the counterintuitive
ﬁnding that the low dose of teduglutide had a higher responder
rate than the high dose. When considering absolute parenteral
volume reductions along with the results of the secondary end
points including the bowel mucosa and plasma citrulline
concentrations, it seems likely that the two active teduglutide
doses exhibit similar efﬁcacy.
Neither active treatment arms resulted in a signiﬁcant
reduction in the number of days on parenteral support.
However, the algorithm for weaning parenteral support did not
specify for conversion of accumulated effects into days off
parenteral support. Many investigators probably found it easier
to just reduce daily parenteral volumes. It was noteworthy that
two patients in the 0.05 mg/kg/day dose group and one patient
in the 0.10 mg/kg/day dose group were completely weaned off
parenteral support.
Although the absolute parenteral volume only tended to
decrease compared with placebo (p¼0.08) in relation to treat-
ment with the two teduglutide doses, the parenteral volume
reduction was not associated with detrimental effects on plasma
creatinine, body weight or body composition. Unfortunately,
renal function was not measured speciﬁcally in this study, but
a recent study suggests that long-term GLP-2 treatment may
have beneﬁcial effects on renal function as evidenced by
improvements in creatinine clearance.
20 Since it seems that
GLP-2 only affects splanchnic and not renal blood ﬂow,
improvement in ﬂuid balance and reductions in episodes of
dehydration may have accounted for this positive effect.
15
It is encouraging that reductions in parenteral energy
amounting to 44761051 kJ/day (p¼0.030) and 91261333 kJ/
day (p¼0.001) in the 0.10 mg/kg/day and the 0.05 mg/kg/day
teduglutide groups, respectively, compared with baseline did not
lead to reductions in body weight. Although measurements of
dietary energy intake and faecal energy excretions were not
measured in this study, it is likely that teduglutide may have
decreased faecal energy losses. In the pilot phase 2 study where
metabolic balance studies were performed, the reduction in
faecal loss was of the same magnitude as the parenteral energy
reductions in this study (80861453 kJ/day).
22 However, in this
study we cannot exclude the possibility that the patients with
SBS may have increased their spontaneous oral energy intake in
relation to parenteral energy reductions. The small parenteral
Table 7 Treatment-emerging adverse events (AEs) and serious
adverse events (SAEs)
Placebo
(n[16)
Teduglutide
0.10 mg/kg/day
(n[32)
Teduglutide
0.05 mg/kg/day
(n[35)
Subjects with AE, n (%) 15 (94%) 31 (97%) 33 (94%)
Subjects with SAE, n(%) 5 (31%) 11 (34%) 13 (37%)
Subjects with any AE or SAE leading
to study discontinuation, n (%)
1* (6%) 2* (6%) 6 (17%)
Event description by system organ class
Cardiac disorders 0 0 1
Cardiac failure congestive 0 0 1
Gastrointestinal disorders 0 2 6
Abdominal distension 0 0 1
Constipation 0 0 2
Haemorrhoidal haemorrhage 0 0 1*
Nausea 0 0 1
Pancreatitis 0 1 0
Small intestinal obstruction 0 1* 0
Vomiting 0 0 1
General disorders and administration
site conditions
00 1
Asthenia 0 0 1
Infections and infestations 1* 1* 0
Catheter sepsis 1* 1* 0
Investigations 0 0 1
Drug level increased 0 0 1
Nervous system disorders 0 0 3*
Coma 0 0 1*
Dysgeusia 0 0 1*
Hypersomnia 0 0 1*
If a subject experienced more than one adverse event in a category, the subject was
counted only once in that category. Each event was counted.
*Serious adverse event. Coma, dysguesia and hypersomnia were all found in one patient.
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Small bowelvolume and energy reduction in the placebo patients emphasises
the fact that closely followed patients have the ability to reduce
parenteral support and underscores the importance of intestinal
rehabilitation programmes. It is noteworthy that, even in dedi-
cated centres managing to recruit patients for this study, the
numbers of patients receiving adequate conventional antidiar-
rhoeal and antisecretory medication seems low (table 2). In
general, it is prudent to use these conventional therapies before
additional therapies are considered.
Seeking to identify patients especially suitable for teduglutide
treatment, no signiﬁcant correlation was found between residual
length of small bowel and the ability to wean from parenteral
support in any of the groups (with or without a colon in
continuity) or in all the groups put together. When the data
from the two teduglutide treatment groups were pooled both
the responder rate and GRS were signiﬁcantly better than
placebo (p¼0.03 and p¼0.04, respectively). However, reductions
in parenteral volume and the composite effects were still only of
borderline signiﬁcance compared with placebo (p¼0.051 and
p¼0.07, respectively). A signiﬁcant correlation was found
between the baseline parenteral volume and the absolute
parenteral volume reductions at week 24 (r¼0.44, p¼0.0006),
suggesting that the largest absolute effect of teduglutide
occurred in patients with the worst remnant bowel function.
However, this adds to the argument that a difference in baseline
parenteral volume was not the only explanation for the
discrepancy between the two teduglutide dose groups with
regard to the effect on the primary efﬁcacy end point.
A potential limitation of the current study is that endogenous
postprandial meal-stimulated GLP-2 production was not
measured. It could be speculated that patients with the largest
remnant L-cell massdthat is, patients with residual ileum and
colon
27dwould have the higher endogenous GLP-2 secretions to
start with and therefore might be less likely to respond since
they already may have been sensitised to stimulation. In fact,
68% of patients with SBS recruited to this study had part of the
colon in continuity which would have masked the full potential
of teduglutide. In this study we found no signiﬁcant difference
in the percentage reduction in volume of parenteral support
between those with and without a colon in continuity. The
doses of teduglutide given in this study are known to give rise to
supraphysiological teduglutide levels even compared with the
elevated endogenously-secreted GLP-2 levels in patients with
a preserved colon.
28 Previous balance studies suggest that tedu-
glutide was equally beneﬁcial in patients with SBS with
a preserved colon and those with a jejunostomy or ileostomy.
22
As part of the safety evaluation, all patients with a preserved
colon had a screening colonoscopy at baseline and were
re-screened at week 24 to exclude the occurrence of premalig-
nant or malignant lesions. Although neither GLP-2 nor tedu-
glutide have been shown to be an independent risk factor for the
development of colonic adenomas, dysplasia or malignancy, it
was reassuring that no polyps were found on colonoscopy and
that histopathological evaluation of the intestinal tissue samples
conﬁrmed no dysplasia transformation in any of the 390
individual biopsies taken in relation to this study.
As a sign of the potency of the drug, small bowel biopsy data
showed that treatment with teduglutide increased villus height
and crypt depth, although the data rest on only a subset of the
patients with SBS who were willing to have small bowel biop-
sies taken. In the colon the crypt depth only increased signiﬁ-
cantly in the patients receiving 0.10 mg/kg/day teduglutide.
These beneﬁcial effects on bowel morphology are also in accor-
dance with ﬁndings in the phase 2 study.
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The statistically signiﬁcant increases in fasting plasma
citrulline concentrations in both groups supported the intesti-
notrophic effects of teduglutide. Earlier studies have shown that
fasting plasma citrulline correlates with residual bowel length in
patients with SBS.
23 This can be explained by the fact that
enterocytes of the small intestine are unique in the body in being
able to synthesise and export citrulline to the blood. Thus, the
intestinotrophic effects of teduglutide may not account for all
the effects on intestinal wet weight absorption. Effects on
gastric emptying and secretions are also likely and may need to
be further investigated.
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The number of subjects reporting an AE and the number of
AEs were distributed similarly across all groups. Equally, the
distribution of the number of subjects reporting SAEs was
similar between groups. Many of the AEs leading to the
discontinuation of active treatment in this study have been
described previously with native GLP-2 treatment.
21 They were
mainly related to the pro-absorptive and intestinotrophic effects
of teduglutide or restrictions in the parenteral weaning algo-
rithm. It is likely that a more individualised parenteral adjust-
ment algorithm and modiﬁcation to medications that had
narrow therapeutic windows and variable bioavailability may
have prevented several of these AEs. However, the occurrence of
small intestinal obstruction with teduglutide warrants a degree
of caution to be exercised when used in patients with a history
of abdominal pain and recurrent small bowel obstructions.
Increased intestinal ﬂuid absorption, which is desirable in the
majority of patients with SBS, could cause concern in patients
with latent or overt cardiac decompensation if the parenteral
ﬂuid infusions are not weaned accordingly.
It must be acknowledged that the quality of life tools used in
this trial were not speciﬁc for patients with SBS. No improve-
ments in health-related quality of life in relation to teduglutide
treatment could be demonstrated when employing generic
measures such as the SF-36, EQ-5D and IBDQ tools. However,
since there is large heterogeneity in the symptoms of patients
with SBS, it is likely that the beneﬁts perceived in relation to
teduglutide treatments could translate into heterogeneous
outcomes not speciﬁcally captured by the tools employed. In
addition, the study was likely to be underpowered to detect
clinically meaningful changes, and the small number of subjects
in this study hindered meaningful subgroup analyses. Owing to
the large heterogeneity of patients with SBS with intestinal
failure, it is difﬁcult to evaluate the clinical meaningfulness of
the suggested beneﬁts of teduglutide at present. However,
although few in number, the signiﬁcance of actually getting
three patients off all parenteral support should not be under-
estimated. Furthermore, the concomitant reduction in faecal
excretions may also be perceived as a great advantage, especially
in patients with SBS with rectum and colon in continuity, large
diarrhoeas and fear of faecal incontinence, but also in patients
with SBS with jejunostomies or ileostomies and large stomal
output which may limit their social interaction. Although
teduglutide may not directly decrease the incidence of catheter-
related complications, any reduction in the time that patients
with SBS are dependent on their central line and parenteral
support is beneﬁcial.
In conclusion, teduglutide was safe, well tolerated and
demonstrated restoration of structural and functional integrity
of the remaining intestine with signiﬁcant intestinotrophic and
proabsorptive effects facilitating reduction in parenteral support
in patients with SBS with intestinal failure. Teduglutide has the
potential to reduce dependency on parenteral support and its
side effects. We suggest that the study design, the parenteral
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Small bowelweaning algorithm and imbalance at baseline regarding the need
for parenteral support probably jeopardised the effect of the
0.10 mg/kg/day dose of teduglutide on the primary efﬁcacy end
point of the study. However, the ad hoc statistically signiﬁcant
effect of the 0.05 mg/kg/day dose on the primary end point and
the effects on secondary end points conﬁrmed the overall
potency of both doses of teduglutide. A conﬁrmatory phase 3
study will be conducted. Adjustments to the parenteral weaning
algorithmdallowing for earlier and more aggressive parenteral
weaningdhave been made and the 0.05 mg/kg/day teduglutide
dose is to be employed. Further studies will determine whether
the reductions in parenteral volumes translate into reduced
complications in relation to parenteral support and even
improvements in quality of life. SBS disease-speciﬁc question-
naires are currently in development for this purpose. Studies of
longer duration are needed to determine whether patients with
milder forms of SBS and intestinal failure can be weaned
permanently from parenteral support and be made orally
autonomous. The effect of longer dosing in relation to response
is unclear, although data from early reports from the short-term
teduglutide study suggest that the beneﬁcial effects of teduglu-
tide are reversible within 3 weeks after terminating treatment.
22
This suggests that chronic long-term treatment probably will be
necessary to maintain the beneﬁts seen in parenteral reductions.
An opportunity may exist to study a possible additional effect of
teduglutide in the acute adaptive period after intestinal resec-
tion. Studies in children with SBS are also warranted as the
complications in relation to parenteral support are even more
predominant in this group of patients.
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